Domestic hyperlipidemia drug market in transition

Published: 2012-11-07 07:00:00

Updated: 2012-11-07 07:00:00

The local hyperlipidemia drug market is undergoing a major transformation as Janssen’s Crestor (rosuvastatin)is likely to overtake Pfizer’s Lipitor (atorvastatin) in sales, reshuffling the leader board of a popular drug.

Lipitor kept its number 1 ranking in terms of revenue over the past years...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK